Data-driven analysis backed by 1,400+ primary-sourced biopharma transactions. Licensing benchmarks, negotiation strategies, and market intelligence.
Ipsen has executed 8 deals since 2017, with a sharp pivot toward hematology driving its most recent — and largest — transactions. Here's what their deal activity tells BD teams, founders, and investors about where Ipsen is heading and how to position assets accordingly.
Vaccine deal activity exploded from zero transactions to 17 in six months — a 1700% surge driven by Big Pharma pipeline anxiety and next-gen platform bets. Eli Lilly and Sanofi are leading the charge with multi-billion-dollar total deal values. Here's what BD teams need to know right now.
Bispecific antibody licensing activity exploded from 1 deal to 19 deals in six months — an 1800% surge. Pfizer alone committed over $12.5B in total deal value across two 3SBio transactions. Here's what's driving the spike and what it means for BD teams negotiating right now.
ADC licensing activity surged 1900% between February and August 2026, jumping from 1 deal to 20. GSK, Novartis, and a wave of mid-cap buyers are driving the most aggressive ADC deal cycle in a decade — and the structural implications for BD teams are significant.
Small molecule licensing activity exploded 3067% between the first and second halves of the trailing twelve months, jumping from 3 deals to 95. The data points to a structural shift in Big Pharma pipeline strategy — and the deal tables from July 2026 confirm it.
Rare disease deal activity exploded 3400% between February and August 2026, jumping from 1 deal to 35. Five deals alone exceeded $1.9B in total deal value. Here's what's driving it, who's buying, and what BD teams should do right now.
Deal activity in the 'other' category — spanning tools, platforms, diagnostics, and enabling technologies — jumped 3400% in the first half of 2026, going from zero deals to 34. Merck KGaA's $11.3B Bio-Techne acquisition and Pfizer's $2B YaoPharma licensing deal anchor a trend that reshapes how BD teams should think about non-traditional therapeutic assets.
Mega-deal activity exploded from zero to 61 transactions between February and August 2026 — a 6100% increase. We break down the drivers, the landmark deals, and what this means for BD teams negotiating billion-dollar structures right now.
Other modality deals jumped from 7 to 96 in six months — a 1271% increase that represents the most dramatic category surge in 2026 dealmaking. The data points to Big Pharma aggressively filling pipeline gaps in non-traditional modalities, and the deal structures reflect it.
Oncology deal activity exploded from 5 transactions to 79 in six months — a 1480% increase that signals a fundamental reset in how Big Pharma is sourcing pipeline assets. The data points to a seller's market with no signs of cooling.
Hematology deal activity exploded from zero transactions to 16 in six months — a 1600% increase that signals a fundamental shift in Big Pharma pipeline strategy. The Incyte-Vega Therapeutics deal alone carried a $2B total deal value. Here's what's driving the surge and what it means for BD teams negotiating hematology licensing in 2026.
Vaccine deal activity exploded 1700% in the first half of 2026, jumping from zero transactions to 17 in six months. Eli Lilly and Sanofi are leading a land grab that's reshaping vaccine licensing 2026 dynamics — and BD teams need to recalibrate now.
Bispecific antibody licensing activity jumped from 1 deal to 19 in six months — an 1800% surge driven by Big Pharma pipeline anxiety and platform-level acquisitions. Here's what the data says and what it means for your next negotiation.
ADC licensing activity exploded by 1900% between February and August 2026, jumping from 1 deal to 20 in a single six-month window. GSK, Novartis, and Whitehawk led the charge with multi-billion-dollar total deal values. Here's what's driving it and what it means for your next negotiation.
Small molecule licensing activity exploded from 3 deals to 95 in six months — a 3067% increase. The surge is driven by Big Pharma pipeline anxiety, degrader platform maturation, and a strategic pivot away from biologics risk. Here's what the data says and what BD teams should do about it.
Rare disease licensing activity exploded by 3400% in the first half of 2026, jumping from 1 deal to 35 in a single six-month period. Five deals alone cleared $1.9B in total deal value. Here's what's driving the surge and what it means for your next negotiation.
Other licensing 2026 has exploded from zero deals to 34 in six months — a 3400% increase driven by platform technology acquisitions and cross-therapeutic partnerships. The Bio-Techne/Merck KGaA mega-deal alone signals a structural shift in how pharma values enabling technologies.
Mega-deal activity exploded from zero to 61 transactions between February and August 2026 — a 6100% surge. We dissect the drivers, the standout deals, and the tactical implications for every BD team in biopharma.
Mega-deal activity exploded from zero to 61 transactions in the first half of 2026 — a 6100% increase period over period. Eli Lilly, GSK, and Ipsen are leading a land grab that's reshaping deal structures and leverage dynamics across biopharma BD.
Other deal activity jumped 3600% in the first half of 2026, leaping from zero recorded deals to 36 in six months. Mega-transactions like Merck KGaA's $11.3B Bio-Techne acquisition and Pfizer's $2B YaoPharma licensing deal are rewriting the playbook for cross-category dealmaking.
Mega-deal activity exploded from zero to 61 transactions between February and August 2026 — a 6100% surge that rewrites the competitive playbook for BD teams. Here's what's behind it and what it means for your next negotiation.
AbCellera and Vertex have formed a partnership to develop next-generation T-cell engagers, signaling sustained Big Pharma appetite for differentiated oncology platforms. We break down what the deal structure likely looks like against current biopharma deal benchmarks 2026 and what it means for BD teams evaluating similar assets.
Johnson & Johnson has secured an option to acquire in vivo CAR-T developer Sail Bio for nearly $2.6B — blowing past Phase 2 immunology total deal value benchmarks by a significant margin. The structure signals how seriously Big Pharma is pricing next-generation cell therapy delivery, and what BD teams need to know before their next CAR-T negotiation.
Mega-deal activity exploded from zero to 61 transactions in the first half of 2026 — a 6100% increase. Eli Lilly, GSK, and Ipsen are leading the charge. Here's what's driving the surge and what it means for BD teams right now.
Deal activity classified as "other" — including platform technology acquisitions, tools licensing, and cross-sector partnerships — surged 3900% in the first half of 2026. Merck KGaA's $11.3B Bio-Techne deal and Pfizer's $2B YaoPharma partnership signal a structural shift in how pharma is sourcing innovation.
Get data-driven deal terms for any therapeutic area, modality, and clinical phase. Powered by 1,400+ primary-sourced biopharma transactions.
Try Solidus
